Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Legend Biotech (LEGN): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow LEGN for free
Share

Sections with a free account

8 concentrated managers hold it (+1 vs last quarter); combined they have held more shares for 2 quarters in a row (2 added, 0 trimmed). Its median weight in those portfolios is 2.1%.

Who owns Legend Biotech?

Legend Biotech trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): FMR, 15.0% (13G/A filed Aug 6, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were FMR (29.1 million ADRs), Deerfield Management (8.1 million ADRs) and Montanova Capital (7.1 million ADRs).

Which institutions hold the most Legend Biotech shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. FMR: 29.1 million ADRs
  2. 2. Deerfield Management: 8.1 million ADRs
  3. 3. Montanova Capital: 7.1 million ADRs
  4. 4. Hhlr Advisors: 6.0 million ADRs
  5. 5. BlackRock: 4.7 million ADRs
  6. 6. Westfield Capital Management: 4.4 million ADRs
  7. 7. Goldman Sachs Group: 3.7 million ADRs
  8. 8. Point72 Asset Management: 3.1 million ADRs
  9. 9. Kynam Capital Management: 3.0 million ADRs
  10. 10. Assenagon Asset Management: 1.9 million ADRs

Sources:13G/A by FMR (Aug 6, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Legend Biotech revenue

Legend Biotech reported annual revenue of $1.03 billion for fiscal year 2025 (year ended December 31, 2025), according to its Form 20-F filed with the SEC (XBRL data).

Concentrated managers
8
All 13F: 219
Consensus
57/100
across 8 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$28.88
+59.6% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (7 → 8): 3 opened · 2 exited = +1

Net flow in the quarter: +$44.4M (+1.5 M shares) · bought $113M and sold $68.7MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Accumulation: combined they have held more shares for 2 quarters in a row (2 added, 0 trimmed). It is the combined share count of those still holding it: one large buyer can outweigh many who trimmed.

The set of concentrated managers changed between quarters: with the set as it was then, 6 held it last quarter (the chart point); with today's set, 7 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of LEGN (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

Fiscal 2025 figures (annual report on Form 20-F, IFRS accounting standards) · balance sheet as of Dec 31, 2025.

Profitability
Operating margin
-13.3%
Net margin
-28.8%
ROE
-29.6%
Growth
Revenue (TTM)
$1.0 bn
Revenue growth
64.0%
Net income (TTM)
$-297M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
$-129M
Quality vs sector
—

Figures come from the latest annual report: we do not compare them with its sector's, which are 12-month figures to the latest quarter. Debt includes leases: under IFRS 16 they are all on the balance sheet and their cost sits outside EBITDA.

Figures from the statements the company filed with the SEC (20-F). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 368.6 M

368.6 M0
20202025
1 year
+0.8%
3 years
+15.9%
5 years
+56.0%
Buybacks (FY 2025)
no data
Share issuance
no data
Stock-based compensation
$64.6M6.3% of revenue
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
−15.6 timesnegative operating income
Debt due within 12 months
$327M0.36 times cash and investments

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • FMR15%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 6, 2026
  • FMR13.1%13G · amendmentfiling ↗Event: Dec 31, 2025 · filed: Feb 5, 2026
  • FMR15%13G · amendmentfiling ↗Event: Sep 30, 2025 · filed: Nov 5, 2025

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow LEGN for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow LEGN